Compare EIG & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EIG | INBX |
|---|---|---|
| Founded | 2000 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 754.0M | 999.7M |
| IPO Year | 2006 | 2024 |
| Metric | EIG | INBX |
|---|---|---|
| Price | $43.31 | $106.01 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $150.00 |
| AVG Volume (30 Days) | 165.4K | ★ 612.3K |
| Earning Date | 04-29-2026 | 05-15-2026 |
| Dividend Yield | ★ 2.99% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.52 | N/A |
| Revenue | ★ $858,700,000.00 | $1,300,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.26 | N/A |
| P/E Ratio | $80.63 | ★ N/A |
| Revenue Growth | N/A | ★ 550.00 |
| 52 Week Low | $35.73 | $12.80 |
| 52 Week High | $49.79 | $155.29 |
| Indicator | EIG | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 62.20 | 47.94 |
| Support Level | $42.44 | $69.30 |
| Resistance Level | $43.31 | $153.14 |
| Average True Range (ATR) | 1.17 | 13.39 |
| MACD | 0.04 | -4.17 |
| Stochastic Oscillator | 96.52 | 14.75 |
Employers Holdings Inc is a provider of workers' compensation insurance and services focused on small and mid-sized businesses engaged in low-to-medium hazard industries. Its customers are employers, and the insurance premiums that those employers pay to account for company revenue. Substantially all of the remaining revenue is generated through investments. The company operates exclusively in the United States, and it generates more than half of its business in California. By industry, the company has exposure to restaurants, which account for roughly a fourth of the total premiums the company earns. It operates as a single reportable segment, Insurance Operations through its wholly owned subsidiaries.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.